Risks

Subscale liquidity, with a current ratio of 0.6 and quick ratio of 0.6, leaves AKTX more exposed than better-capitalized peers to funding pressure if operating losses persist.

Negative interest coverage of -31.5x indicates earnings are not supporting financing costs, making AKTX materially weaker than profitable biotech peers with self-funding profiles.

Minimal leverage does not offset the liquidity strain, because low debt only helps if cash generation improves, whereas peers with stronger balance sheets can absorb longer development cycles.

With no visible working-capital cushion in the latest metrics, AKTX appears less resilient than peers that maintain higher current assets and broader access to non-dilutive capital.

Opportunities

Low debt-to-equity of 0.04 and net debt-to-EBITDA near zero reduce balance-sheet drag versus leveraged peers, preserving optionality if clinical or commercial catalysts emerge.

If operating performance improves, the absence of heavy debt service could let AKTX convert incremental revenue more efficiently than peers burdened by higher fixed financing costs.

The current capital structure is simpler than many development-stage biotech peers, which can support relative flexibility in partnering or financing negotiations.

Because leverage is already limited, any external improvement in funding conditions would likely benefit AKTX more than peers with tighter covenant or refinancing pressure.

Overall Score

AKTX’s low leverage provides some optionality, but weak liquidity and deeply negative interest coverage leave it more exposed than better-capitalized peers.